Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Farmers Insurance
McKinsey
Harvard Business School
Julphar
Medtronic
Cipla
Citi
Chinese Patent Office
Fuji

Generated: May 27, 2018

DrugPatentWatch Database Preview

Claims for Patent: 6,689,761

« Back to Dashboard

Summary for Patent: 6,689,761
Title: Combination therapy for HIV infection
Abstract:The combination of the HIV protease inhibitor Compound J, 3TC, and, optionally AZT, ddI, or ddC, is useful in the inhibition of HIV protease, the inhibition of HIV reverse transcriptase, the prevention or treatment of infection by HIV and the treatment of AIDS, either as compounds, pharmaceutically acceptable salts, pharmaceutical composition ingredients, whether or not in combination with other antivirals, immunomodulators, antibiotics or vaccines. Methods of treating AIDS and methods of preventing or treating infection by HIV are also described.
Inventor(s): Chodakewitz; Jeffrey A. (Gwynedd Valley, PA), Emini; Emilio A. (Paoli, PA)
Assignee: Merck & Co., Inc. (Rahway, NJ)
Application Number:08/382,113
Patent Claims: 1. A combination of compounds, which is Compound J, nucleoside analog HIV reverse transcriptase inhibitor 3TC, and nucleoside HIV reverse transcriptase inhibitor AZT, or a pharmaceutically acceptable salt or ester thereof.

2. The method of claim 1, wherein the combination is administered simultaneously.

3. The method of claim 1, wherein the combination is administered alternatively.

4. A method of inhibiting HIV protease, comprising administering to a suitable mammal in need of such treatment an effective amount of the combination of claim 1.

5. A method of inhibiting HIV reverse transcriptase, comprising administering to a suitable mammal in need of such treatment an effective amount of the combination of claim 1.

6. A method of treating infection by HIV, AIDS or ARC, comprising administering to a suitable mammal in need of such treatment an effective amount of the combination of claim 1.

7. A pharmaceutical composition useful for inhibiting HIV protease, comprising an effective amount of the combination of claim 1, and a pharmaceutically acceptable carrier.

8. A pharmaceutical composition useful for inhibiting HIV reverse transcriptase, comprising an effective amount of the combination of claim 1, and a pharmaceutically acceptable carrier.

9. A pharmaceutical composition useful for treating infection of HIV, or for treating AIDS or ARC, comprising an effective amount of the combination of claim 1, and a pharmaceutically acceptable carrier.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Covington
McKinsey
McKesson
Queensland Health
Boehringer Ingelheim
Citi
Teva
Chinese Patent Office
Argus Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.